Physician

Matthew C Wilson, MD

According to 2025 Medicare claims, Matthew Wilson, MD (NPI: 1891726295) practices allergy/immunology in the Huntington-Ashland, WV-KY-OH market, with the plurality of this provider's patient population coming from Cabell, WV. This provider's primary affiliated billing organization is TRI-STATE ALLERGY, INC (NPI: 1386786796; TIN: 550650197) and primary practice location at 41101-2807.

Wilson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 350 traditional Medicare patients, billed 47,804 HCPCS/CPT codes, and received $1,014,174 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 6,346 prescription claims across 663 beneficiaries totaling $2,108,527 in drug costs, led by Dupixent Pen (Dupilumab). DME data shows 154 claims. Open Payments data shows 125 records totaling $95,283. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $89,779 to $1,014,174. Similarly, Part D prescription costs have moved sharply higher in recent years, from $377,414 to $2,108,527. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,898 and ending at $3,811.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	298	8,025	$89,779
2016	332	10,944	$108,313
2017	416	16,928	$203,134
2018	376	18,350	$318,503
2019	367	22,666	$457,320
2020	346	27,673	$607,022
2021	396	32,408	$676,478
2022	361	38,543	$806,447
2023	354	46,621	$963,516
2024	350	47,804	$1,014,174

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	369	3,081	$377,414
2016	372	3,280	$421,105
2017	478	4,738	$656,923
2018	499	5,175	$782,777
2019	487	4,717	$727,998
2020	494	4,958	$934,594
2021	556	5,203	$1,128,412
2022	581	5,613	$1,657,531
2023	621	5,936	$2,058,960
2024	663	6,346	$2,108,527

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	200	$21,735
2016	11	191	$86,571
2017	30	216	$18,722
2018	14	187	$5,846
2019	33	303	$12,102
2020	32	158	$1,859
2021	N/R	99	$1,432
2022	N/R	94	$2,787
2023	N/R	145	$74,301
2024	N/R	154	$78,084

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	281	450	$77
94375	Test to measure rate of airflow	171	290	$24
95012	Test to measure the level of nitric oxide gas	176	289	$11
95165	Professional service for preparation and provision of 1 or more antigens	142	4,713	$8
95115	Professional service for single injection of allergen	120	3,307	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Pen	Dupilumab	79	2,212	$345,038
Nucala	Mepolizumab	72	2,240	$287,886
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	252	10,230	$217,019
Spiriva Respimat	Tiotropium Bromide	176	9,000	$150,278
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	14	343	$137,703

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	15	$75,261
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	16	$1,104
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	23	$569
E0570	Nebulizer, with compressor	Y	N/R	64	$531
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	N	N/R	19	$418

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	123	$12,683	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$82,600	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew C. Wilson, MD?

Tedicare shows public-source Medicare data for Matthew C. Wilson, MD (NPI 1891726295), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew C. Wilson, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Matthew C. Wilson, MD?

Matthew C. Wilson, MD is linked to TRI-STATE ALLERGY, INC (billing NPI 1386786796) in the available physician profile data.

Does Matthew C. Wilson, MD have Open Payments data?

Matthew C. Wilson, MD has 125 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.